Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,340
Distinct drugs
372
Records naming a cancer
982
Dated in the last 12 months
181
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 48 | Sep 22, 2026 |
| EMA | EU | 459 | 245 | 385 | 74 | 18 | Jul 20, 2026 |
Data updated 21 hours agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| — | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-OXALIPLATIN INJECTION (DIN 02446227) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug… | DIN02446227 | withdrawnsource: Cancelled Pre Marketsince Jul 29, 2021 | health-canada-dpd |
| — | Docetaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT DOCETAXEL 40 MG/ML (DIN 02444410) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product… | DIN02444410 | withdrawnsource: Cancelled Pre Marketsince Jul 24, 2020 | health-canada-dpd |
| — | Peginterferon Beta-1a | Health Canada CA | cancer not stated in this record | Marketed in Canada as PLEGRIDY (DIN 02444380) under ATC L03AB13 PEGINTERFERON BETA-1A. Indications are not published in the Drug Product… | DIN02444380 | approved | health-canada-dpd |
| — | Peginterferon Beta-1a | Health Canada CA | cancer not stated in this record | Marketed in Canada as PLEGRIDY (DIN 02444372) under ATC L03AB13 PEGINTERFERON BETA-1A. Indications are not published in the Drug Product… | DIN02444372 | approved | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-TEMOZOLOMIDE (DIN 02443546) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02443546 | approved | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02442833) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02442833 | withdrawnsource: Cancelled Pre Marketsince Sep 30, 2024 | health-canada-dpd |
| — | Docetaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT DOCETAXEL 40 MG/ML (DIN 02441845) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product… | DIN02441845 | withdrawnsource: Cancelled Pre Marketsince Jul 24, 2020 | health-canada-dpd |
| — | Temsirolimus | Health Canada CA | cancer not stated in this record | Marketed in Canada as GD-TEMSIROLIMUS (DIN 02441810) under ATC L01EG01 TEMSIROLIMUS. Indications are not published in the Drug Product… | DIN02441810 | withdrawnsource: Cancelled Pre Marketsince Dec 22, 2022 | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEMETREXED DISODIUM FOR INJECTION (DIN 02441616) under ATC L01BA04 PEMETREXED. Indications are not published in the… | DIN02441616 | withdrawnsource: Cancelled Pre Marketsince Feb 28, 2022 | health-canada-dpd |
| — | Glatiramer | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-GLATIRAMER ACETATE (DIN 02441446) under ATC L03AX13 GLATIRAMER ACETATE. Indications are not published in the… | DIN02441446 | approved | health-canada-dpd |
| — | Topotecan | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEVA-TOPOTECAN (DIN 02441063) under ATC L01CE01 TOPOTECAN. Indications are not published in the Drug Product Database… | DIN02441063 | approved | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION, USP (DIN 02437171) under ATC L01BC05 GEMCITABINE. Indications are not published in the… | DIN02437171 | withdrawnsource: Cancelled Pre Marketsince Jul 13, 2022 | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION, USP (DIN 02437163) under ATC L01BC05 GEMCITABINE. Indications are not published in the… | DIN02437163 | withdrawnsource: Cancelled Pre Marketsince Jul 13, 2022 | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION, USP (DIN 02437155) under ATC L01BC05 GEMCITABINE. Indications are not published in the… | DIN02437155 | withdrawnsource: Cancelled Pre Marketsince Jul 13, 2022 | health-canada-dpd |
| — | Docetaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-DOCETAXEL (DIN 02436388) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database… | DIN02436388 | withdrawnsource: Cancelled Pre Marketsince Mar 15, 2023 | health-canada-dpd |
| — | Docetaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as PMS-DOCETAXEL (DIN 02436361) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database… | DIN02436361 | withdrawnsource: Cancelled Pre Marketsince Mar 15, 2023 | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT GEMCITABINE (DIN 02436205) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product… | DIN02436205 | withdrawnsource: Cancelled Pre Marketsince Apr 27, 2020 | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT GEMCITABINE (DIN 02436191) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug Product… | DIN02436191 | withdrawnsource: Cancelled Pre Marketsince Apr 27, 2020 | health-canada-dpd |
| — | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-CAPECITABINE (DIN 02434512) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02434512 | approved | health-canada-dpd |
| — | Capecitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-CAPECITABINE (DIN 02434504) under ATC L01BC06 CAPECITABINE. Indications are not published in the Drug Product… | DIN02434504 | approved | health-canada-dpd |
| — | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as OXALIPLATIN INJECTION USP (DIN 02433206) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug… | DIN02433206 | approved | health-canada-dpd |
| — | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as OXALIPLATIN INJECTION (DIN 02431688) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product… | DIN02431688 | withdrawnsource: Cancelled Pre Marketsince Oct 26, 2018 | health-canada-dpd |
| — | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as STASON-LETROZOLE (DIN 02431335) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product… | DIN02431335 | withdrawnsource: Cancelled Pre Marketsince Jun 27, 2018 | health-canada-dpd |
| — | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT OXALIPLATIN (DIN 02430533) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product… | DIN02430533 | withdrawnsource: Cancelled Pre Marketsince Jul 24, 2018 | health-canada-dpd |
| — | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT OXALIPLATIN (DIN 02430525) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product… | DIN02430525 | withdrawnsource: Cancelled Pre Marketsince Jul 24, 2018 | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT PEMETREXED (DIN 02428784) under ATC L01BA04 PEMETREXED. Indications are not published in the Drug Product… | DIN02428784 | withdrawnsource: Cancelled Pre Marketsince Jul 24, 2018 | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT PEMETREXED (DIN 02428776) under ATC L01BA04 PEMETREXED. Indications are not published in the Drug Product… | DIN02428776 | withdrawnsource: Cancelled Pre Marketsince Jul 24, 2018 | health-canada-dpd |
| — | Pemetrexed | Health Canada CA | cancer not stated in this record | Marketed in Canada as ACT PEMETREXED (DIN 02428768) under ATC L01BA04 PEMETREXED. Indications are not published in the Drug Product… | DIN02428768 | withdrawnsource: Cancelled Pre Marketsince Jul 24, 2018 | health-canada-dpd |
| — | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-IMATINIB (DIN 02428326) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database —… | DIN02428326 | approved | health-canada-dpd |
| — | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-IMATINIB (DIN 02428318) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database —… | DIN02428318 | approved | health-canada-dpd |
| — | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as MYLAN-IMATINIB (DIN 02424509) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database… | DIN02424509 | withdrawnsource: Cancelled Pre Marketsince Oct 2, 2018 | health-canada-dpd |
| — | Imatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as MYLAN-IMATINIB (DIN 02424495) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database… | DIN02424495 | withdrawnsource: Cancelled Pre Marketsince Oct 2, 2018 | health-canada-dpd |
| — | Axitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as INLYTA (DIN 02422891) under ATC L01EK01 AXITINIB. Indications are not published in the Drug Product Database — see… | DIN02422891 | withdrawnsource: Cancelled Pre Marketsince Mar 31, 2025 | health-canada-dpd |
| — | Axitinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as INLYTA (DIN 02422883) under ATC L01EK01 AXITINIB. Indications are not published in the Drug Product Database — see… | DIN02422883 | withdrawnsource: Cancelled Pre Marketsince Mar 31, 2025 | health-canada-dpd |
| — | Cisplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CISPLATIN INJECTION (DIN 02422034) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product… | DIN02422034 | approved | health-canada-dpd |
| — | Carboplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CARBOPLATIN INJECTION, BP (DIN 02420228) under ATC L01XA02 CARBOPLATIN. Indications are not published in the Drug… | DIN02420228 | approved | health-canada-dpd |
| — | Fludarabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as FLUDARABINE PHOSPHATE INJECTION (DIN 02416069) under ATC L01BB05 FLUDARABINE. Indications are not published in the… | DIN02416069 | approved | health-canada-dpd |
| — | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as OXALIPLATIN FOR INJECTION (DIN 02413841) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug… | DIN02413841 | withdrawnsource: Cancelled Pre Marketsince Oct 25, 2018 | health-canada-dpd |
| — | Oxaliplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as OXALIPLATIN FOR INJECTION (DIN 02413833) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug… | DIN02413833 | withdrawnsource: Cancelled Pre Marketsince Oct 25, 2018 | health-canada-dpd |
| — | Epirubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as EPIRUBICIN HYDROCHLORIDE INJECTION (DIN 02413221) under ATC L01DB03 EPIRUBICIN. Indications are not published in the… | DIN02413221 | approved | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-TEMOZOLOMIDE (DIN 02413132) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02413132 | approved | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-TEMOZOLOMIDE (DIN 02413124) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02413124 | approved | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-TEMOZOLOMIDE (DIN 02413116) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02413116 | approved | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-TEMOZOLOMIDE (DIN 02413094) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02413094 | approved | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-TEMOZOLOMIDE (DIN 02413043) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02413043 | approved | health-canada-dpd |
| — | Temozolomide | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-TEMOZOLOMIDE (DIN 02413035) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product… | DIN02413035 | approved | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02412101) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug… | DIN02412101 | approved | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02412098) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug… | DIN02412098 | approved | health-canada-dpd |
| — | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02412071) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug… | DIN02412071 | approved | health-canada-dpd |
| — | Idarubicin | Health Canada CA | cancer not stated in this record | Marketed in Canada as AJ-IDARUBICIN (DIN 02411679) under ATC L01DB06 IDARUBICIN. Indications are not published in the Drug Product Database… | DIN02411679 | withdrawnsource: Cancelled Pre Marketsince Nov 3, 2015 | health-canada-dpd |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.